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Abstract
Vaccination of Mauritian cynomolgus macaques with the attenuated nef-truncated C8 variant of SIVmac251/32H (SIVmacC8)
induces early, potent protection against pathogenic, heterologous challenge before the maturation of cognate immunity.
To identify processes that contribute to early protection in this model the pathogenesis, anatomical distribution and viral
vaccine kinetics were determined in relation to localised innate responses triggered by vaccination. The early biodistribution
of SIVmacC8 was defined by rapid, widespread dissemination amongst multiple lymphoid tissues, detectable after 3 days.
Cell-associated viral RNA dynamics identified mesenteric lymph nodes (MLN) and spleen, as well as the gut mucosae, as
early major contributors of systemic virus burden. Rapid, localised infection was populated by discrete foci of persisting
virus-infected cells. Localised productive infection triggered a broad innate response, with type-1 interferon sensitive IRF-7,
STAT-1, TRIM5a and ApoBEC3G genes all upregulated during the acute phase but induction did not prevent viral
persistence. Profound changes in vaccine-induced cell-surface markers of immune activation were detected on
macrophages, B-cells and dendritic cells (DC-SIGN, S-100, CD40, CD11c, CD123 and CD86). Notably, high DC-SIGN and
S100 staining for follicular and interdigitating DCs respectively, in MLN and spleen were detected by 3 days, persisting 20
weeks post-vaccination. Although not formally evaluated, the early biodistribution of SIVmacC8 simultaneously targets
multiple lymphoid tissues to induce strong innate immune responses coincident at the same sites critical for early
protection from wild-type viruses. HIV vaccines which stimulate appropriate innate, as well as adaptive responses, akin to
those generated by live attenuated SIV vaccines, may prove the most efficacious.
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Introduction
Development of an effective vaccine against HIV/AIDS
remains an important global public health target. Modest but
short-lived efficacy has been obtained in a recent human vaccine
trial using an avipox vector prime and Envelope subunit boost [1].
However, to make a major impact on the pandemic, improved
vaccine strategies that elicit durable, broadly effective, potent
protection will be required. Live attenuated vaccination (LAV)
with simian immunodeficiency virus (SIV) in non-human primates
has provided proof of concept of highly efficacious vaccine
protection [2,3], demonstrating durable, potent resistance against
detectable superinfection with wild-type SIV challenge by multiple
routes and with diverse virus strains [4–20]. Identification of the
mechanism(s) of protection has proven to be difficult, perhaps, at
least in part, due to the focus on the measurement of responses in
the peripheral circulation. Indeed, the largest study conducted to
date has confirmed the absence of immune responses associated
with vaccine protection in peripheral blood [11].
Moreover, potent vaccine-generated protection and resistance
to superinfection in vivo may be generated shortly after
vaccination with certain attenuated SIV strains [18,19,12,7,8], at
a time when the cognate immune response is absent or immature
in quantity and quality. Hence, we were interested to characterise
the innate immune responses generated in the early, immediate
post-vaccination phase. Whilst it is unclear whether a single
mechanism mediates protection at early and late times after
vaccination, the relative contributions of both the cognate adaptive
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and innate arms of the immune response are important to define,
particularly since innate responses have been relatively understud-
ied and will likely influence protective adaptive responses [21,22]. A
valuable feature of live attenuated vaccines is the ability to stimulate
long-lived protective immunity. Moreover, in common with live
vaccines in general, the degree of protection conferred by
attenuated SIV is inversely proportional to the degree of viral
attenuation [13,23]. Despite the overall success of live attenuated
vaccines, it is only recently that the immune parameters of this
vaccine approach are being unravelled. Increasingly, the impor-
tance of cognate innate signalling in the conditioning of appropriate
adaptive immune responses is being realised [24]. While safety
concerns prevent the direct application of live lentivirus vaccine
approaches in humans, defining the protective processes elicited by
attenuated SIV may inform the design of novel approaches for a
safe, durable and effective vaccine against HIV.
In our studies conducted in the Mauritian cynomolgus macaque
(MCM, Macaca fascicularis) model with the attenuated nef-
disrupted C8 variant of SIVmac251/32H (SIVmacC8), we have
been able to demonstrate that protection against wild-type strains
can be generated as early as 21 days after vaccination [17,18,7,8],
including against heterologous viral challenge [7]. As efficient
vaccine replication in vivo appears to be a crucial prerequisite to
long-term protection and early vaccine virus replication leads to
changes in lymphocyte populations in gut-associated lymphoid
tissue [25], we sought to understand the viral kinetics in vivo at
multiple localised sites of infection and how localisation and
dissemination of the SIVmacC8 virus influences innate responses
associated with vaccination/infection. Mauritian CM provide an
excellent model to examine this topic, representing a genetically
well-characterised host with a limited host MHC composition due
to founder population effects [26–30].
In a detailed early pathology study of the infecting time-course
we describe how the SIVmacC8 vaccine virus is rapidly
established in an early, widespread and persisting infection in
multiple lymphoid tissues (LT), which is by no means confined to
the gut mucosae. Concurrent with this localised infection of LT,
we identify concomitant early stimulation of components of the
innate immune system. We analysed the induction of a range of
anti-viral factors including TRIM5a, ApoBEC3G (A3G), BST-2/
tetherin, TRIM22 [31–39], the dendritic and myeloid restriction
factor SAMHD1 [40–41] and mediators of type-1 interferon
signalling STAT-1 and IRF-7. In parallel, cell surface expression
changes of markers of cell lineages orchestrating innate immune
responses including macrophages and dendritic cells (DC) [42–44]
were induced as early as day 3, which persisted in the MLN and
spleen coincident with persisting vaccine virus replication.
In determining the biodistribution of this live attenuated SIV we
unravelled a strong induction of aspects of innate immunity which
occur in tandem in multiple tissues in response to a localised and
persisting vaccine virus. Persistence of this viral vaccine 3–20
weeks post-vaccination appears to drive a concomitant localised
and persisting innate response, not confined to the gut mucosae.
The implications of these findings in studies of early live
attenuated SIV vaccine protection are discussed and pave the
way for further detailed differential studies of viral vaccine
protection.
Results
Distribution and kinetics of intracellular virus in lymphoid
tissue
A total of 16 Mauritian cynomolgus macaques, for which the
MHC haplotype had been determined (Figure S1), were
inoculated intravenously with SIVmacC8 in an early pathology
study of live attenuated SIV. Groups of animals were sequentially
sacrificed at days 3, 7, 10 and 21 across the acute phase
(Figure 1A). For comparison, two macaques were monitored into
the chronic phase of infection and sacrificed at 125 days post
infection (d.p.i.) for additional tissue analysis. Individual plasma
viral RNA (vRNA) kinetics of each macaque indicated all were
infected to comparable levels displaying highly reproducible
vRNA kinetics between individuals (Figure 1B). Peripheral viral
load peaked 10 days p.i. (4.5–5.5 log10 SIV RNA copies/ml); all
vaccinates subsequently displayed a controlled profile of plasma
vRNA kinetics, although macaques E9 and E10 differed slightly in
their long-term control of plasma viraemia to 125 days p.i.
(Figure 1B).
The quantity and distribution of SIVmacC8 cell-associated
RNA (CA-RNA) in multiple lymphoid tissues, compared by real-
time quantitative PCR (qRT-PCR; Figures 2A, B) and in situ
hybridisation (ISH, Figure 3, Table S1), revealed intracellular viral
kinetics of early infection to be defined by a rapid and
simultaneous dissemination of SIVmacC8 to multiple lymphoid
tissues. Tissue-specific differences were compared with baseline
ISH data generated from a total of 15 naı¨ve Mauritian
cynomolgus macaques; the distribution and number of viral foci
for each tissue were related to these. Early dissemination of
SIVmacC8, characterised by CA-RNA detected 3 days p.i. in
organised lymphoid tissues of superior and inferior mesenteric
lymph nodes (MLN), spleen, small and large intestines was
reflected by the presence of virus-infected foci detected by ISH in
MLN, spleen and small intestine (SI). Typically, the concentration
of CA-RNA determined by qRT-PCR and frequency of virus-
infected cells as shown in Figures 2 and 3 increased over time in all
tissues, peaking 7–21 days p.i. SIVmacC8 thus established an
active, persisting infection in all tissues sustained beyond the
immediate cessation of the primary viraemic phase. This was
corroborated by both ISH and qRT-PCR, although some subtle
tissue-specific differences were identified (Figures 2 and 3, Table
S1).
Contributions of different lymphoid tissues to the total
viral burden
All tissues sampled supported actively replicating virus, not
limited to any one anatomical site. Each compartment contributed
to the total systemic virus burden reflected in plasma vRNA load
in peripheral blood during acute infection. Comparisons of
concentrations of CA-RNA levels for the 6 lymphoid regions
sampled (inferior and superior MLN, large and small intestine,
spleen and thymus) and the total plasma vRNA at each sampling
point (Figure 2C) identified a positive correlation in all tissues.
Inferior and superior MLN CA-RNA concentrations particularly
showed a high degree of correlation with plasma virus, in terms of
production and cessation of virus during the acute phase. The
lower correlation between splenic CA-RNA and plasma vRNA
can be accounted for by the delayed peak in intracellular RNA to
day 21 (Figure 2A, B), where concentrations in this tissue
remained high when virus levels in the blood have begun to wane
(days 10–21 p.i.). Hence, the intracellular virus concentrations in
the MLN most closely correlated with the dynamics of the primary
plasma viraemia.
Overall viral spread and expansion reflected in these increased
CA-RNA concentrations were accompanied by a greater density
of viral foci identified at day 10 in spleen and MLN, although
there was not always a direct correlation between the number of
viral foci and concentrations of SIV RNA in different tissues. In
the MLN, detection of viral RNA by ISH was maximal at day 10
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in the germinal centres, follicular marginal and mantle zones. In
the small intestine, foci of infection were observed in primary
follicles, follicular and mantle zones and germinal centres at day 3.
By day 7, virus had spread to the villi tips and at the peak of
primary virus replication (days 10–21) had invaded the lamina
propria. Virus persistence was reflected in overall distribution in
the small intestine at day 125 with virus detected in the Peyer’s
patches, germinal centres and lamina propria (Figure 3). Tracking
of virus through the small intestine, MLN and spleen indicated
that by day 21 p.i., all three tissues were characterised by
persisting virus-infected cells that expressed viral RNA.
Cell-associated viral DNA (vDNA) levels showed a similar
picture although, as expected, CA-RNA loads were a more
sensitive measure of intracellular virus (Figure S2).
Induction of restriction factors in multiple lymphoid
tissues
The impact of localised virus replication on induction of known
restriction factors (RF) and interferon-stimulated genes (ISG) was
assessed using the total RNA extracted in Figure 2. Relative gene
expression levels were determined by qRT-PCR for TRIM5a,
ApoBEC3G, BST-2/tetherin, TRIM-22, SAMHD-1, STAT1 and
IRF7 comparing levels in naı¨ve macaques normalised to GAPDH
(Figure 4). ISGs IRF-7 and STAT-1 were induced 7–10 d.p.i.,
particularly in blood, coincident with peak virus production. Not
all RF genes were upregulated in all tissues. ApoBEC3G and
TRIM5a mRNAs were upregulated during acute SIVmacC8
infection, though not in all tissues. This could not be attributed to
the presence of different TRIM5a genotypes since only three
TRIM5a genotypes are present amongst these Mauritian animals
with no TRIM-cyp variants and the qPCR used has been
validated for these sequences [29,30]. Tetherin mRNA was poorly
induced in tissues, although tetherin mRNA levels peaked in
PBMC. As expected, there was no IFN-dependent upregulation of
SAMHD1 [40,41,45] nor, more surprisingly, TRIM22 mRNA.
Hence, SIVmacC8 induced transient, sporadic induction of
selective antiretroviral RFs in at least three LT. It is difficult to
determine the impact of RF/ISG induction due to differences in
viral kinetics and host responses among a limited number of
animals. Low numbers in each group also precluded a formal
statistical analysis of the relationship between RF/ISG induction
and tissue-specific viral load, although there was a clear trend
Figure 1. Study time-course and plasma vRNA levels. A) Schematic outline of experimental details. Pairs of juvenile MCM were serially
sacrificed at days 0, 3, 7, 10, 21, 125 post intravenous vaccination with 0.5 ml of a 1/10 dilution of the 9/90 pool of SIVmacC8. Intermediate blood
sampling times are indicated by red arrows. B) Plasma viral RNA levels determined by qRT-PCR at each time point for plasma samples collected
during acute infection (days 3, 7, 10 and 21 p.i.) and the chronic phase (day 125). Macaques analysed post-mortem were (E1, E2, G1, G2, day 3; E3, E4,
day 7; E5, E6, G3, G4, day 10; E7, E8, G5, G6, day 21 and E9, E10, day 125).
doi:10.1371/journal.pone.0104390.g001
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towards upregulation coincident with high levels of CA-RNA in
different LT. Moreover, it is clear that RF activation elicited
during peak infection, did not prevent persistence of SIVmacC8
and its widespread distribution among multiple LT.
SIVmacC8 activates a broad spectrum of markers of
innate immune function
Further evidence for innate immune activation after vaccination
was sought by detection of a range of cell surface activation
markers expressed on DCs, macrophages and B-cells in the SI,
MLN and spleen by immunohistochemistry (IHC, Figures 5 and
6, Table S2; Figures S3 and S4). Following vaccination with
SIVmacC8 there was widespread innate immune activation
measured by upregulation of all markers assessed by blinded
scoring above baseline levels of naive, unvaccinated MCM. The
kinetics of induction differed between tissues. In the small intestine,
DC markers CD11c, (a type 1 transmembrane protein), CD123,
(an IL-3 receptor also found on plasmacytoid dendritic cells
(pDC)), CD86, (expressed on antigen presenting cells providing co-
stimulatory signals for T-cell priming) and the macrophage marker
CD68 all had very similar profiles exhibiting a marked upregula-
tion in response to acute infection but returning to low levels 21–
125 days p.i., mainly in the crypts and lamina propria (Figure 6).
Upregulation of the CD123 marker suggests pDCs are recruited to
the small intestine and transiently activated during acute infection.
As pDCs are potent secretors of IFN-a, their transient induction is
consistent with an acute response to virus infection in the gut that
is not sustained in chronic infection and compatible with a burst of
ISG induction (Figure 4).
Upregulation of granzyme B and perforin was observed 3–21
days p.i. in all three lymphoid tissues (Figure S5), reflecting the
primary virus replication profile, before returning to baseline.
Broad parameters of immune function including CD4, CD8 and
Figure 2. Rapid and widespread dissemination of SIVmacC8 to multiple lymphoid tissues during the acute phase of infection.
Panels A, B. Cell-associated (CA)- RNA concentrations determined over the time-course in tissue-derived cells. 50 ng total RNA extracted from
tissue-derived cells was processed in a one-step probe-based qRT-PCR. SIV gag copy number derived from a standard curve was normalised to 56105
copies of GAPDH. Histograms represent average values from 2 (time points 7 and 125 days p.i.) or 4 (0, 3, 10 and 21 days p.i.) animals, performed in
duplicate in at least two independent experiments (6SEM). SIV gag copy number was plotted against time in days post-inoculation (panel A), or
grouped by tissue (panel B). Data were obtained for superior and inferior mesenteric lymph nodes (MLNs and MLNi, respectively), spleen, thymus
and small and large intestine. * denotes results obtained from a single animal. Downward arrows indicate no signal detected – all tissues at day 0,
(naı¨ve, baseline) or in the thymus at days 3, 7 and 21. Panel C shows the relationship between plasma vRNA levels and CA-RNA levels for each tissue.
Log10 values are represented as a scatter plot and the correlation between the two variables determined by linear regression analysis with r
2 values
are shown.
doi:10.1371/journal.pone.0104390.g002
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CCR5 varied among tissues p.i. (Figure S5). Importantly,
additional markers of DC activation, eg CD40, (a member of
the TNFa superfamily) were induced to high levels 3–7 d.p.i. in
the MLN and SI, but this upregulation persisted through to
125 d.p.i. CD40 expression varied in the spleen and was only
expressed to high levels during acute infection. Differences in
markers of innate immune function between local sites of infection
suggest a complex innate immune response to vaccination, as
might be expected.
SIVmacC8 vaccination induces sustained DC-SIGN
expression in MLN and spleen but not small intestine
IHC detection of different markers of innate immune function
revealed that the spleen and MLN exhibited significant acute
responses but importantly, also sustained upregulation of multiple
markers persisting into chronic infection. DC-SIGN and S100
(markers of follicular and interdigitating DCs), CD40, CD11c,
CD123, CD86, as well as CD68 and CD20 all exhibited high
levels of expression at 21 d.p.i in spleen (Figure 5, Figure S3);
however, only DC-SIGN, S100, CD86 and CD68 maintained
persistent, high expression 125 d.p.i. Critically, we identified high
levels of DC-SIGN, S100 and CD68 staining as early as 3 d.p.i.,
which persisted to chronic infection in MLN and spleen (Figures 5
and 7). Intense staining for DC-SIGN antigen was also found in
the red pulp, follicular margins and mantle zones of the spleen but
not in the SI. S100 staining was at intermediate levels 3–21 d.p.i.
and maximal 125 d.p.i. in the SI. Images of comparative staining
intensities for CD40, CD11c, CD123 and CD86 in spleen, MLN
and SI are as shown in Figure 6 and Figures S4 and S5.
Overall, the data suggest that both cellular and cell-autonomous
innate immune responses are activated at early time points after
SIVmacC8 vaccination but persist only in selected tissues, notably
MLN and spleen. Finally, the B cell marker CD20 was expressed
at intermediate levels during acute infection but higher in the
chronic phase in different tissues (Figure 5, Figure S6).
Figure 3. SIVmacC8 establishes persisting foci in infection in multiple lymphoid tissues. Galleries of representative fields of in-situ
hybridisation of sections of spleen, MLN and small intestine in MCM inoculated with SIVmacC8 and sacrificed at 0 (naı¨ve) 3, 7, 10, 21 and 125 days
post infection (d.p.i). Heatmap staining representing the overall frequency of foci of virus-infected cells in multiple fields is shown beneath individual
panels. Location of foci of virus-infected cells are represented as indicated: pf – primary follicles, pp - peyers patches; pc – paracortex, rp – red pulp, gc
– germinal centre, mg – follicular marginal/mantle zone, ms – medullary sinuses, lp – lamina propria, vt – villi tips within each main tissue type and
indicated by arrows. Samples from naive, uninfected macaques are shown as controls. Magnification was 620, main image; 680 inset. In situ
hybridisation for combined SIV gag/env/nef (g/e/n) messenger RNA conform to the same classification of staining intensity as IHC for comparative
purposes: pale yellow (no staining, 2); yellow (very low, +); dark yellow (medium, ++), red (high, +++), corresponding to the mean number of positive
cells/mm2: + (0.5–6.8), ++ (6.9–13.8) and +++ (.13.8) cells/mm2 also represented in Table S1.
doi:10.1371/journal.pone.0104390.g003
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Discussion
Identification of critical immune responses that might need to
be elicited by an effective HIV vaccine represents a crucial
milestone for logical vaccine development. Live attenuated SIV
vaccination of macaques delivers potent protection that correlates
with in vivo replication efficiency of the viral vaccine [13,23].
Nonetheless, LAV strains characteristically exhibit low or unde-
Figure 4. Induction of interferon-dependent genes in tissue-derived cells. Expression levels of interferon signalling genes (IRF-7, STAT-1),
restriction factors (TRIM5a, APOBEC3G, tetherin, SAMHD1, TRIM-22), and ribosomal protein L32 (RPL32) were represented as fold difference from
levels in naı¨ve macaques, after normalisation using housekeeping gene GAPDH. Data are plotted for mesenteric lymph nodes, small intestine, spleen
and blood across the time course from naı¨ve (day 0) to 3, 7, 10, 21 and 125 d.p.i. Histograms represent average values from 2–4 animals 6 SEM. The
equivalent of 50 ng of reverse transcribed total RNA was used in a SYBR-green based qPCR.
doi:10.1371/journal.pone.0104390.g004
Figure 5. Heatmap showing cell surface staining for dendritic cells, macrophages and B cells. Staining intensities are as indicated shown
for dendritic cell markers (DC-SIGN, S100, CD40, CD11c, CD123, CD86), macrophages (CD68) and B cells (CD20). Relative localisation of staining within
each tissue are represented by: pc – paracortex, rp – red pulp, wp - white pulp, gc – germinal centre, mg – follicular marginal/mantle zone, ms –
medullary sinuses, c – crypts, lp – lamina propria, within each main tissue type. Mab, monoclonal antibody. IHC gradings: pale yellow (no staining, 2);
yellow (very low, +); dark yellow (low, ++), red (medium, +++) and magenta (high, ++++).
doi:10.1371/journal.pone.0104390.g005
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tectable steady-state plasma viraemia. Whereas, typically, virus
replication is ongoing in lymphoid tissue [11]. Here, we sought to
understand the anatomical niches, timing and distribution of the
SIVmacC8 viral vaccine at lymphoid sites during the establish-
ment of infection with a view to illuminating vaccine persistence
and identifying local anti-viral responses as potential effectors of
vaccine-mediated protection, focussing on innate responses.
Moreover, the live attenuated SIV vaccine used in this study
profoundly differs from strains used by other groups in that it
confers protection at a time before maturation of cognate
immunity; hence we sought to define the induction of these early
responses.
Intravenous inoculation of live attenuated SIVmacC8 elicited
rapid viral dissemination, reflected in widespread distribution of
actively replicating virus-infected cells among multiple organs
detectable 3–7 days p.i. Concordant data from intracellular SIV-
specific qRT-PCR and in situ hybridisation performed on RNA
purified from disaggregated lymphoid cells and formalin fixed
paraffin embedded tissues respectively, revealed a dynamic picture
of early virus replication not confined to the gut mucosae. While
large numbers of susceptible CD4+ T cells reside in the small
intestine, particularly the lamina propria [46,47], with dynamic
changes in lymphocyte subsets associated with an acute inflam-
matory response immediately post SIVmacC8 vaccination [25],
the MLN and spleen were also identified as major sites of early
vaccine virus replication. CA-RNA levels in MLN most closely
paralleled plasma vRNA kinetics identifying it as a dominant
source of systemic viraemia, in addition to the intestinal mucosae
during acute infection [48–50]. Changes in location and quality of
SIV infection in lymphoid tissues have also been reported in rhesus
macaques (RM) infected with SIVmac239Dnef [11] and in
cynomolgus macaques infected with wild-type SIV [51].
We hypothesise that localised responses at these specific sites of
virus replication in vivo are triggered by SIVmacC8 which may
act either independently, or in concert with other facets of
immunity, to protect these anatomical niches from incoming wild-
type viruses. Persistence of antigen-expressing, virus-infected cells
in target tissues that remain as peripheral viral loads fall supports
this model. Indeed, by 21 days post-vaccination all tissues
exhibited evidence of persisting infection. Although all tissues
were targeted during primary infection and LAV persisted in
multiple tissues, we sought to identify the early responses that
might relate to vaccine protection, particularly measures of innate
immune activation that associate with infected cells. In the
Mauritian model of early SIVmacC8 protection, this may be
particularly pertinent given our previous observations of early
vaccine protection [7,8,18,19].
In this unique longitudinal study of the early parameters of
SIVmacC8 vaccination, the highly reproducible vaccine virus
kinetics, well-characterised MHC background and limited TRIM5
genotype significantly mitigate the relative small study numbers
(n = 2–4) at each time-point. Moreover, the relatively conserved
Figure 6. Expression of dendritic cell markers CD40, CD123, CD11c and CD86 in small intestine. Staining intensities are the same key as
for Figure 5;610 magnification; inset,640, days post SIVmacC8 inoculation.
doi:10.1371/journal.pone.0104390.g006
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genetics of these animals provided a remarkably stable host
background upon which to conduct such studies, given the more
outbred nature of other macaque cohorts, which can confound
study outcomes due to, amongst other things, the impact of
different TRIM5 genotypes [33,34]. Taken together, however, it
was possible to identify a clearly discernible pattern of responses to
infection/vaccination during the critical acute phase where some
responses were clearly transient in nature, while others were more
persistent.
Induction of interferon stimulated genes including restriction
factors and key members of the interferon response pathways
(IRF-7 and STAT-1) suggested a type 1 interferon response to
LAV infection, consistent with previous observations of both SIV
[4] and HIV-1 [52]. However, fold changes in total mRNA
induction were weak, suggesting induction in only a small
percentage of cells. It is highly unlikely that any induction of
TRIM5a in these Mauritian-derived macaques would be biased
by polymorphism, given the limited diversity of TRIM5 genotypes
in this species [29,30]. We therefore assume that TRIM5a did not
present a confounding variable in this study. We used IHC
techniques seeking to specifically identify induction of innate
markers within tissues. As the precise distribution of virus infection
varied between different lymphoid compartments, methods were
used to detect changes in immune cell subsets to identify responses
that might co-localise with the virus.
Although unable to differentiate between upregulation of cell-
surface expression on cells resident in tissues and migrating cells
our data suggest profound immune changes at a local level.
Markers for dendritic cell family members (DC-SIGN, S-100 and
CD40) exhibited expression patterns that, like virus-infected cells,
increase over 3–7 days p.i., and most importantly, were present in
tissues where virus-infected cells persisted (Figures 5–7). This was
particularly apparent in the spleen where elevated expression
persists in the presence of ongoing intracellular viral replication,
and was at its highest level 21 days post vaccination. Viral
persistence and the high splenic virus turnover, suggested by viral
load measurement (Figure 2), is compatible with the early
protection generated by SIVmacC8 as well as with vaccine
recrudescence in protected vaccinates challenged with wild-type
SIV [8,7]. Changes in CD4, CD8, CCR5, perforin and Granzyme
B expression were not associated with development of host control
of viral infection (Figure S5). It is notable that DC-SIGN and
CD68 were upregulated from day 3 p.i. to the highest levels
measured suggestive of a highly sensitive, effective induction of
innate immune responses prior to development of any functionally
relevant adaptive response. We hypothesise that this continued
Figure 7. Rapid induction and persistence of DC-SIGN, S100 and CD68 post-vaccination in lymphoid tissue. Galleries of representative
fields of A DC-SIGN and B CD68 staining in MLN at 3, 7, 10, 21, 125 d.p.i. C Representative fields of DC-SIGN signal tracking through the spleen 3–
125 d.p.i. maximal from d3 in red pulp (rp) and marginal zones (mg) D Representative fields of splenic S100 levels illustrate similar staining intensity
3–125 d.p.i. predominantly in the germinal centres and red pulp. Staining intensities scoring were; pale yellow (no staining, 2); yellow (very low, +);
dark yellow (low, ++), red (medium, +++) and magenta (high, ++++).
doi:10.1371/journal.pone.0104390.g007
Early Distribution of SIV Vaccination Elicits Innate Immunity
PLOS ONE | www.plosone.org 8 August 2014 | Volume 9 | Issue 8 | e104390
stimulation of myeloid lineages, particularly DCs and macrophag-
es in critical tissues, may be an important component of the early
protection generated by live attenuated SIV vaccines with
dendritic and macrophage cell lineages in key anatomical niches
playing a central role in this process. However, inclusion of a
challenge component would be required to formally determine
any association between these observations and the protection
observed in this model.
Studies of other live virus vaccines (eg yellow fever) have shown
strong induction of innate immune signals, including Toll-like
receptors and DCs, which stimulate a robust adaptive response
[53–55]. Yet the specific role of adaptive immunity in the
spectrum of LAV mediated protection is far from clear. Indeed,
there is a conundrum to identify immune responses that a LAV
elicits that is highly effective in preventing infection with
homologous wild-type virus, yet incapable of eliminating the
vaccine virus [56]. Colonisation of immunologically privileged
CD4+ T follicular helper (TFH) cells in the germinal centres of
lymphoid tissue provides one possibility [11,57]. In addition,
trapping and accumulation of viral antigen in follicular dendritic
cells along with recently produced virus provides a mechanism for
continued immune stimulation. High SIVmacC8 RNA concen-
trations in the spleen are compatible with SIV infection of
follicular dendritic cells presenting gag antigen and CD4+ cell
frequencies in LT which occur with increased activation of TFH
cells, but not increased CCR5 expression [58]. Specific analysis of
TFH and their role as an early reservoir of virus infection would
help clarify their contribution to early vaccine protection.
Despite rapid stimulation of CD20-expressing B cells compat-
ible with expansion of the plasmablast during acute infection and
co-resident virus in these cells, there appears to be little evidence,
however, that adaptive humoral responses are directly linked to
host protection [6]. Re-stimulation of memory B-cells during
superinfection frequently boosts antibody titres which appear to
represent a marker of retroviral infection, rather than a protective
correlate. However, strong induction of innate immunity will likely
influence development and maturation of antibodies, even if at low
affinity, which may impact on protective processes. Absence of
adaptive immune correlates of early protection is further
highlighted by CD8+ T cell ablation across a 35 day period
encompassing primary infection which neither prevents control of
the primary viraemia, nor the ability to resist superinfection [19].
However, it remains possible that mechanistically distinct
processes may be operating at early and later times particularly
given demonstration of maturation of protection [3,9,11,13],
where induction of a strong innate response during the early
period may also influence differential processes that occur at later
times.
Depletion of target cells during the early primary phase of virus
replication and dissemination provides one possible alternative
explanation for different protective mechanisms at late and early
times. That multiple lymphoid tissues support vaccine virus
replication soon after intravenous administration and localised
responses are detected in key secondary organs of MLN and
spleen, the ability to resist challenge via different routes (eg
mucosal sites) would be interesting to clarify. Viruses entering via
different sites also track through secondary lymphoid tissues, so
pre-existing vaccine-mediated responses in the spleen and MLN
would likely also be protective in this scenario.
It is also important to recognise that Vpx-encoding viruses
belonging to the HIV-2/SIVsm/SIVmac lineage, such as those
used in this study, may interact quite differently with the innate
immune system than Vpx-negative viruses such as HIV-1. Vpx
antagonises the restriction factor SAMHD1 and may allow
replication in myeloid lineage cells that are not permissive to
HIV-1 in vivo [40,41,59]. Thus, SIVmac-based LAV may elicit a
range of persisting immunological changes, including those which
impact on macrophages and dendritic cell function that may not
directly translate to HIV-1 infection in humans. However,
dissecting the changes that occur in myeloid and lymphoid cell
populations, as recently described with a conditionally replication-
competent vaccine [60], will likely be crucial to understanding
protective mechanisms and identifying novel approaches to HIV
vaccination.
In conclusion, appropriate induction of components of the
innate immune system, in tandem with adaptive responses, may be
a requirement of highly efficacious HIV vaccines.
Materials and Methods
Study design and sample collection
A total of 16 juvenile, weaned Mauritian cynomolgus macaques
were inoculated with 10 MID50 of the SIVmacC8 9/90 pool [61]
and pairs sacrificed at days 3, 7 10, 21, and 125 post inoculation as
previously described [25]. Blood and tissues were collected as
shown in Figure 1A, consisting of inferior (i) and superior (s)
mesenteric lymph nodes (MLN), spleen, small and large intestines.
Ethics statement
Non-human primates were used in strict accordance with UK
Home Office guidelines, under a licence granted by the Secretary
of State for the Home Office which approved the work described.
Animal work at NIBSC is governed by the Animals (Scientific
Procedures) Act 1986 which complies with the EC Directive 86/
609 and performed under licence (PPL 80/1952) granted only
after review of all procedures in the licence by the NIBSC local
Ethical Review Process (ERP). All study macaques were purpose
bred and group-housed for the entire duration of the study, with
daily feeding and access to water ad libitum. Given the limited
availability of suitable macaques, age, sex and weight matching
was not possible, nor central to the study outcome. Regular
modifications to the housing area were made by husbandry staff
including introduction of novel structures (eg swings and perching
stations) and foodstuffs in novel manners to encourage foraging for
food, to further enrich the study environment. The environmental
temperature was 15–24uC, appropriate for macaques and rooms
subject to a 12 hour day/night cycle of lighting. Animals were
acclimatised to their environment and deemed to be healthy by
the named veterinary surgeon prior to inclusion on the study.
All animals were sedated prior to bleeding or virus inoculation
by venepuncture. Frequent checks were made by staff and any
unexpected change in behaviour by individuals on study followed
up, including seeking of veterinary advice where necessary.
Regular blood samples were obtained to assess haematological
parameters in blood that might provide evidence of incipient
disease and veterinary advice sought when persisting abnormalities
detected. The study was terminated and all animals killed
humanely by administering an overdose of ketamine anaesthetic
prior to development of overt symptomatic disease. All efforts were
made to minimise animal suffering, including provision of a high
standard of housing quarters and monitoring of animal health and
well-being and the absence of procedures not essential to the study.
Host genetics
The MHC haplotype and TRIM5 genotype was determined for
all study Mauritian cynomolgus macaques (Macaca fascicularis) as
previously reported [28–30].
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Quantification of SIV RNA levels in plasma
Plasma viral RNA levels were quantified by a real-time qRT-
PCR method as previously described [8]. The sensitivity of
detection was 50 SIV RNA copies/ml plasma.
Cell-associated RNA isolation and quantitative RT-PCR
Total RNA from tissue-derived cells was extracted using an
RNeasy kit (Qiagen) and subjected to on-column DNAase
treatment according to the manufacturer’s instructions. SIV gag
was quantified by adaptation of a one-step quantitative RT-PCR
as previously described [8] with 50 ng of total RNA input. SIV
gag copies were quantified using a standard curve obtained by
serial dilution of the plasmid SIV3+ [62]. Data were expressed as
copies per 50 ng RNA, normalised to a GAPDH house-keeping
gene. Sensitivity of detection was 20 SIV RNA copies/50 ng input
RNA. For quantification of restriction factor transcripts, 500 ng of
total RNA was subjected to reverse transcription using AccuScript
High Fidelity reverse transcription kit (Agilent), in a final volume
of 20 mL, using primers described in Table S3. One tenth of the
reaction was processed in a quantitative PCR (qPCR) using
Quantitect SYBR-Green PCR kit (Qiagen) with 0.4 mM of each
primer. Each reaction was run in duplicate using the Mx3005P
(Agilent), thermocycling conditions were: 50uC, 2 min; 95uC,
15 min; 40 cycles of 95uC, 15 sec, 55uC, 1 min and 60uC, 1 min.
Specificity of qPCR products was assessed by dissociation curves
and quantified using the 22DCt method, and the housekeeping
gene GAPDH as normaliser. For selected genes quantification was
verified using standard curves obtained by serial dilution of
plasmids encoding GAPDH, RPL32, TRIM5a, SAMHD1 or
tetherin. All data were analysed using MxPro software (Agilent).
In situ hybridisation
Representative sections of LT and SI were collected post-
mortem, fixed in 10% formal saline and embedded in paraffin wax
using standard histological procedures. Four micron sections were
cut and mounted on poly-L lysine coated slides. Prior to treatment
sections were de-waxed in xylene and re-hydrated via graded
ethanol:water solutions. In situ hybridisation for detection of SIV
RNA transcripts was performed with digoxigenin (dig; Roche,
Lewes, UK), labelled single stranded DNA probes [51] in a
cocktail containing three sense/antisense probes to SIV transcripts
(gag, env, nef) using a BondMax automated staining machine,
utilising the Research Mode option for protocol design and
execution (Leica Microsystems USA) as previously described [63].
Quantification of ISH positive cells collected post-mortem for
spleen (Spl), mesenteric lymph nodes (MLN) and small intestine
(S.I.) was performed by manually counting all positive cells within
10 random fields of view (610 lens and 610 eye-piece
magnification; equivalent to an area of 2.2 mm2). The mean
number of positive cells/mm2 was expressed using a grading
system of: + (0.5–6.8), ++ (6.9–13.8) and +++ (.13.8) cells/mm3 as
previously reported [7]. Baseline values, 2, (0) were established
from a total of 15 additional uninfected Mauritian cynomolgus
macaques.
Immunohistochemical analyses and antibody staining
Immunohistochemical analyses were performed as previously
described [64]. Unmasking of antigens to allow binding of the
antibody was undertaken by the optimal technique for each
combination of antibody and antigen. Sections were heated at full
power (800W microwave) for five minutes fully immersed in
Vector unmasking solution (Vector Laboratories, Peterborough,
UK) previously heated to 96uC for immunolabelling of CD4
(H370, Santa Cruz Biotechnology Inc, California, USA), CD20
(L26), S100 (DAKO, Ely, Cambridgeshire, UK), DC-SIGN
(120507, R+D Systems Inc, Minneapolis, USA), CD123 (6H6,
eBioscience, San Diego, USA) and CD40 (11E9), CD11c (5D11)
(Novacastra, Leica Microsystems, USA), or 10 mM citrate buffer
(pH 6), KK13 (SIV gp120), [65]. Sections were incubated in
50 mg ml21 proteinase K (Roche, Lewes, UK) in PBS pH 7.4 for
15 minutes at 37uC prior to immunolabelling with CD8 (C8/
144B), CD68 (KP1) (DAKO, Ely, Cambridgeshire, UK), CCR5
(3A9), CD86 (fun-1) (Pharmingen, Oxford, UK), granzyme B
(11F1, Novacastra, Leica Microsystems, USA) and perforin (5B10,
Vector Laboratories, Peterborough, UK). Data were generated by
assessing staining levels across the whole tissue section (at least 5
fields 610 lens/106 eyepiece magnification) on blinded samples
and tabulated results were generated for the mean score of all
animals within that group. Representative fields were selected for
presentation in figures and colour coded relating to the level of
intensity of staining. IHC gradings were: pale yellow (no staining,
2); yellow (very low, +); dark yellow (low, ++), red (medium, +++)
and magenta (high, ++++). Staining levels for individual antibodies
were compared to baseline values for naı¨ve macaques.
Supporting Information
Figure S1 MHC profiles of 16 Mauritian cynomolgus
macaques in the time-course study. Each major haplotype
(M1–M6) is represented by a different colour bar as depicted, or as
a recombinant (rec), for MHC class IA, class IB and class II.
(TIFF)
Figure S2 Quantitative DNA levels of multiple tissues
post SIVmacC8 vaccination. Copies of SIV DNA are
expressed per 100,000 MNCs, error bars shown for multiple
macaques sampled at each time-point. Abbreviations: MLNs and
MLNi, superior and inferior mesenteric lymph node; PLN,
peripheral lymph node. Downward arrows indicate no signal.
(TIFF)
Figure S3 Expression of dendritic cell markers CD40,
CD123, CD11c and CD86 in spleen. Staining intensities are
the same key as for Figure 5;610 magnification.
(TIFF)
Figure S4 Expression of dendritic cell markers CD40,
CD123, CD11c and CD86 in mesenteric lymph nodes
(MLN). Staining intensities are the same key as for Figure 5;610
magnification; inset,640, days post SIVmacC8 inoculation.
(TIFF)
Figure S5 Heatmap showing staining for cell surface
markers for viral env, CD4, CD8, CCR5, granzyme B
and perforin. Monoclonal antibody staining intensities are
shown for SIV env, CD4, CD8, CCR5, granzyme B and perforin.
Relative localisation of staining within each tissue is shown:
represented by the following key: pp; peyers patches; pc –
paracortex, rp – red pulp, 19 – primary follicle, wp - white pulp, gc
– germinal centre, gch, -germinal centre haze, mg – follicular
marginal/mantle zone, ms – medullary sinuses, c – crypts, lp –
lamina propria, vt – villi tips within each main tissue type. Mab,
monoclonal antibody.
(TIFF)
Figure S6 Staining intensities for CD20 B cell marker in
spleen, MLN and small intestine during the time course
of SIVmacC8 infection. Staining intensities as depicted in
Figure 5, days post SIVmacC8 inoculation.
(TIFF)
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Table S1 Quantification of ISH positive cells collected
post-mortem for spleen, mesenteric lymph nodes (MLN)
and small intestine following SIVmacC8 vaccination
(days post-inoculation).
(DOCX)
Table S2 Comparative immunohistochemistry staining
intensities for different markers for dendritic cells,
macrophages and B cells.
(DOCX)
Table S3 Primer sequences for qPCR for multiple gene
targets.
(DOCX)
Checklist S1 ARRIVE Checklist.
(DOC)
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